Cargando…
589. Oral Tablet Vaccination Induces Heightened Cross-Reactive CD8 T Cell Responses to SARS-COV-2 in Humans
BACKGROUND: Covid-19 has accelerated global demand for easily distributed vaccines. Furthermore, as variant SARS-CoV-2 strains that circumvent antibody responses emerge, cross-protective vaccines provide substantial public health benefits. Vaxart is developing a shelf stable oral tablet vaccine that...
Autores principales: | Johnson, Susan, Martinez, Clarissa, Cortese, Mario, Martinez, Josefina, Garg, Shaily, Peinovich, Nadine, Dora, Emery, Tucker, Sean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644266/ http://dx.doi.org/10.1093/ofid/ofab466.787 |
Ejemplares similares
-
Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model
por: Langel, Stephanie N., et al.
Publicado: (2022) -
1960. Mucosal rAd5 Immunization against SARS-CoV-2 Spike Elicits Cross-Reactive Nasal and Serum Neutralizing Antibodies and Protects Against Beta Variant Challenge in African Green Monkeys
por: Flitter, Becca A, et al.
Publicado: (2022) -
The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells
por: Lisiero, Dominique N, et al.
Publicado: (2014) -
589 Urticaria Pigmentosa. Case Report
por: González-Díaz, Sandra, et al.
Publicado: (2012) -
miR-589-5p inhibits MAP3K8 and suppresses CD90(+) cancer stem cells in hepatocellular carcinoma
por: Zhang, Xi, et al.
Publicado: (2016)